- Price basis
- Starting offer, not verified monthly total
- Included per provider
- Review, injection supplies and shipping
Identify the purchase before annualizing it
The current IVY RX injection page advertises NAD+ from $179 and qualifies the offer with a variable-use description. It does not establish that the starting amount purchases thirty days of treatment. We therefore display it as a starting offer, leaving the monthly denominator unresolved instead of multiplying $179 by twelve as though that were a verified annual plan.
The next useful details are the actual vial quantity, concentration, intended supply period and payment schedule. They should correspond to the clinician's prescription and pharmacy label. A review can document those commercial questions without converting a vague package offer into instructions for how much medication a person should use.
What is publicly included
IVY RX's FAQ describes provider review, injection supplies and priority shipping within its quoted price. The page also advertises temperature-controlled delivery. Those statements make it possible to distinguish the offer from a bare medication price, although the contents and shipping arrangements for the final order still need confirmation.
Check whether additional visits, laboratory work when clinically indicated or replacement shipments create separate charges. A general statement that labwork is not required for the advertised intake should not become a recommendation to bypass an evaluation. Clinical assessment and commercial packaging are related parts of a purchase, but they answer different questions.
Read the quality claims precisely
The page displays potency, sterility, endotoxin and pH testing statements. We did not inspect a batch-specific laboratory report or independently verify the named testing process. Ask which dispensing pharmacy supplies the medication, what documentation applies to the actual vial and how to contact that pharmacy about a storage or packaging concern.
FDA has warned about unsuitable food-grade ingredients being used in sterile NAD+ preparations and has received adverse-event reports consistent with excessive endotoxins. That warning does not establish a defect in this provider's product. It explains why ingredient suitability and preparation controls matter more than an attractive vial photograph or a general quality badge.
Injection evidence is not a wellness promise
IVY RX markets the product around energy, focus, recovery and aging. These are claims about potential outcomes, not results measured by this publication. We have not verified a controlled study of the finished IVY RX preparation demonstrating those benefits or a reliable time to notice a difference.
A compounded injection is not FDA-approved, even if its manufacturer or dispensing facility is registered with FDA. Ask the clinician what concern is being addressed, what evidence supports the proposed route and what alternatives should be considered. New or persistent symptoms deserve assessment rather than an automatic explanation based on age or NAD+ levels.
Compare the refill, not just the first vial
The most informative comparison pairs the complete first order with the next expected order. Request both prices, the refill interval, cancellation terms and how follow-up is handled. That prevents a low entry amount from being mistaken for a stable recurring expense before the actual supply duration is known.
IVY RX provides a clearly named injection offering and a useful list of advertised inclusions. Its current weakness for cost comparison is the missing denominator behind the starting price. Readers who prefer a nasal format should use the separate spray review, since matching headline amounts do not make the preparations interchangeable.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.